Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. by Kaneda, Kazuhiro et al.
Thomas Jefferson University
Jefferson Digital Commons
Cardiology Faculty Papers Department of Cardiology
1-1-2008
Sevoflurane enhances ethanol-induced cardiac
preconditioning through modulation of protein
kinase C, mitochondrial KATP channels, and nitric
oxide synthase, in guinea pig hearts.
Kazuhiro Kaneda
Osaka Dental University
Masami Miyamae
Osaka Dental University
Shingo Sugioka
Osaka Dental University
Chika Okusa
Osaka Dental University
Yoshitaka Inamura
Osaka Dental University
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/cardiologyfp
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
This article has been peer reviewed. It is the authors' final version prior to publication in Journal of the American College of Surgeons
Volume 207, Issue 5, November 2008, Pages 758-762. The published version is available at . DOI: 10.1016/j.jamcollsurg.2008.06.341.
Copyright © Elsevier Inc..
Authors
Kazuhiro Kaneda, Masami Miyamae, Shingo Sugioka, Chika Okusa, Yoshitaka Inamura, Naochika Domae,
Junichiro Kotani, and Vincent M. Figueredo
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/cardiologyfp/6
As submitted to: Anesthesia and Analgesia 
 and later published as: Anesthesia and Analgesia 
Volume 106, Issue 1, January 2008, Pages 9-16 
10.1213/01.ane.0000297298.93627.36 
 
Sevoflurane Enhances Ethanol-Induced Cardiac Preconditioning 
Through Modulation of Protein Kinase C, Mitochondrial KATP 
Channels, and Nitric Oxide Synthase, in Guinea Pig Hearts 
 
 
Kazuhiro Kaneda, DDS*, Masami Miyamae, MD, PhD£, Shingo Sugioka, DDS, PhD#, 
Chika Okusa, DDS*, Yoshitaka Inamura, DDS*, Naochika Domae, MD, PhD&, 
Junichiro Kotani, DDS, PhD§, Vincent M. Figueredo, MD¶ 
 
*Postdoctoral Researcher, #Assistant Professor, §Professor, Department of Anesthesiology, 
Osaka Dental University, Osaka, Japan 
£Assistant Professor, &Professor, Department of Internal Medicine, Osaka Dental University, 
Osaka, Japan 
¶Institute for Heart and Vascular Health, Albert Einstein Medical Center, Philadelphia, USA  
 
This study was supported in part by Grant-in-Aid for Scientific Research (C) 16592032 from the 
Ministry of Education, Culture, Sports, Science and Technology of Japan (MM), the Osaka Dental 
University Joint Research Founds (MM, ND), and the Science Research Promotion Fund from the 
Promotion and Mutual Aid Corporation for Private Schools of Japan (ND). 
 
Conflict of Interest: The authors have no conflicts of interest to report. 
 
Key Words: sevoflurane, preconditioning, ethanol, mitochondrial KATP channel, protein kinase 
C, nitric oxide synthase 
 
Corresponding Author & Reprints: Masami Miyamae, MD, PhD 
Department of Internal Medicine,  
  
 
2
Osaka Dental University 
8-1 Kuzuha hanazono-cho Hirakata, 
Osaka 573-1121, Japan 
TEL : 81-72-864-3079, FAX : 81-72-864-3179 
E-mail: kyotomiya@hotmail.com 
Short Title: Sevoflurane and ethanol preconditioning  
  
 
3
Implication Statement 
Sevoflurane enhances cardiac preconditioning induced by regular ethanol consumption, an 
effect, mediated in part by PKC and mitochondrial KATP channels. Modulation of NOS 
expression by regular ethanol consumption may also play a role in this enhanced 
cardioprotection. 
Abstract 
Background: Volatile anesthetics and regular ethanol consumption induce cardioprotection 
mimicking ischemic preconditioning. We investigated whether sevoflurane enhances ethanol 
preconditioning and whether inhibition of protein kinase C (PKC) and mitochondrial KATP 
channels attenuated this enhanced cardioprotection. The effects of regular ethanol consumption 
on expression of inducible (iNOS) and endothelial (eNOS) nitric oxide synthase were determined.  
Methods: Isolated perfused guinea pig hearts underwent 30 min global ischemia and 120 min 
reperfusion (Control:CTL). The ethanol group (EtOH) received 2.5% ethanol in their drinking 
water for 6 weeks. Anesthetic preconditioning was elicited by 10 min exposure to sevoflurane (1 
MAC; 2%) in ethanol (EtOH+SEVO) or non-ethanol (SEVO) hearts. PKC and mitochondrial 
KATP channels were inhibited with chelerythrine (CHE) and 5-hydroxydecanoate (5-HD) 
pretreatment, respectively. Contractile recovery was assessed by monitoring of left ventricular 
developed (LVDP) and end-diastolic (LVEDP) pressures. Infarct size was determined by 
triphenyltetrazolium chloride staining. Expression of iNOS and eNOS were determined by 
Western blot analysis.  
Results: After ischemia-reperfusion, hearts from the EtOH, sevoflurane (SEVO), and 
EtOH+SEVO groups had higher LVDP and lower LVEDP compared with CTL. Infarct size was 
reduced in EtOH and SEVO hearts compared with CTL (27% and 23% vs. 45%, respectively, 
p<0.001). Sevoflurane further reduced infarct size in EtOH hearts (27% vs. 15%, p<0.001). CHE 
and 5-HD abolished cardioprotection in both SEVO and EtOH cardioprotected hearts. iNOS 
expression was reduced and eNOS expression was increased in EtOH hearts.  
Conclusions: Sevoflurane enhances cardiac preconditioning induced by regular EtOH 
consumption. This effect is mediated in part by modulation of PKC and mitochondrial KATP 
channels, and possibly by altered modulation of NOS expression.  
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Introduction  
Volatile anesthetics induce cardiac preconditioning in a manner similar to ischemic 
preconditioning.1 Since Kersten et al.2, first documented anesthetic preconditioning with 
isoflurane, investigators have sought to elucidate the involved mechanisms mediating this 
cardioprotection. Recently, sevoflurane was shown to confer additional cardioprotection to 
late ischemic preconditioning, mediated via mitochondrial KATP channels.
3
 These data 
suggests that sevoflurane may enhance cardioprotection in myocardium, which is already 
preconditioned.  
Epidemiological studies have shown that mortality rates for people who regularly 
drink alcohol in moderation are lower than in abstainers, primarily due to decreased fatal 
ischemic heart disease.4-7 Further, moderate alcohol consumers have lower mortality from 
myocardial infarction compared with abstainers.8 These beneficial cardiac effects may be 
due to the pleiotropic effects of ethanol on lipids9, platelets, and fibrinolytic activity.10,11 We 
have demonstrated that regular ethanol consumption renders hearts more tolerant to 
ischemia-reperfusion injury, to a degree similar to acute ischemic preconditioning.12-14 We 
found this ethanol-induced preconditioning is mediated through myocyte adenosine A1 
receptor12,13 and protein kinase C (PKC) activation.14 Ethanol and volatile anesthetics-
induced cardiac preconditioning, thus, appear to share common signaling pathways. Guiraud 
et al.15, confirmed that the combination of ethanol and ischemic preconditioning were 
synergistic in reducing infarct size.  
We hypothesized that anesthetic preconditioning with sevoflurane would enhance 
ethanol-induced myocardial preconditioning, and that this effect is potentially mediated by 
PKC activation and modulation of mitochondrial KATP channels.
16
 Both sevoflurane and 
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acute ethanol exposure increase nitric oxide release.17,18 Thus, we examined the effect of 
chronic ethanol exposure on the expression of inducible and endothelial nitric oxide 
synthases (iNOS and eNOS).  
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Methods 
This study was conducted in accordance with the Guidelines for Animals Research 
at Osaka Dental University (ODU), and with the approval of the Animal Experiment 
Committee of ODU, Osaka, Japan. Male Hartley guinea pigs were fed Lab Diet (RC4TM, 
Oriental Yeast, Tokyo, Japan) and given water ad libitum.   
 
Isolated Heart Perfusion and Measurement of Function 
Animals weighing 650-700g were given heparin (1000 units i.p.), then anesthetized 
with pentobarbital (60 mg/kg i.p). The hearts were excised and immediately arrested in cold 
isosmotic saline containing 20 mmol/L KCl. The aorta was cannulated and the isolated 
hearts perfused at 70 mmHg on a nonrecirculating isovolumic perfused heart apparatus, 
using a Krebs-Henseleit (KH) perfusate (mmol/L): 118 NaCl, 4.0 KCl, 2.52 CaCl2, 24.8 
NaHCO3, 1.7 MgSO4, 1.2 KH2PO4, 11.0 glucose, 0.5 EDTA and 8 units/L insulin. The 
perfusate was insufflated continuously with 95%O2/5%CO2. The hearts were paced at 240 
beats/min using platinum-tipped electrodes connected to a Grass Instruments (Quincy, MA, 
USA) SD-5 stimulus generator. Left ventricular developed pressure (LVDP) was measured 
from a 2.5 French, high-fidelity micromanometer (Nihon-Kohden, Tokyo, Japan) passed 
into a compliant latex balloon inserted into the LV, and recorded on a PowerLab 2/20 Data 
Recording System (ADInstruments, Hayward, Australia). The balloon was connected to a 
Y-adapter with one end used to advance the micromanometer and the other used to fill the 
LV balloon with bubble-free water to an end-diastolic pressure (LVEDP) of 10 mmHg. The 
maximum rate of increase of LV pressure (+dP/dtmax) and the minimum rate of decrease of 
LV pressure (-dP/dtmin) were calculated using ChartTM5 (ADInstruments). Coronary flow 
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(CF) was measured by collecting effluent. Global ischemia was achieved by clamping the 
aortic inflow line. Temperature of the heart was continuously monitored by a digital 
thermometer (PTW-100A, Unique Medical, Japan). During ischemia, hearts were 
maintained at 37 °C by enclosure in a water-jacketed air chamber. Warmed perfusate kept in 
the lower part of the chamber saturated the air with humidity and prevented cooling by 
evaporation. 
 
Experimental Protocol 
Animals were assigned to one of 8 groups (n=10 each; Figure 1). Animals were 
initially given 1.25 % ethanol in their drinking water for 1 week and then 2.5 % ethanol for 
6 weeks. Serum ethanol levels at time of sacrifice were measured by gas chromatography 
(Shimadzu, Kyoto, Japan). Liver enzymes were measured to rule out the possible liver tissue 
damage.   
After a 20 min equilibration, baseline LVDP, LVEDP and CF were recorded. All 
hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion. Anesthetic 
preconditioning was elicited by administration of sevoflurane (2%) for 10 min followed by 
10 min washout before ischemia. Sevoflurane was insufflated by passing the 
95%O2/5%CO2 gas mixture through a calibrated vaporizer (ACOMA, Tokyo, Japan). 
Samples of coronary perfusate were collected anaerobically from the aortic cannula for 
measurement of sevoflurane concentration by an organic vapor sensor (OSP, Saitama, 
Japan).  To investigate the role of PKC and mitochondrial KATP channels activation, their 
inhibitors chelerythrine (CHE) and 5-hydroxydecanoate (5-HD) were administered for 20 
min, starting 10 min before sevoflurane (EtOH+SEVO+CHE, EtOH+SEVO+5HD) or saline 
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vehicle (CTL+CHE, CTL+5HD) administration. Chelerythrine (Alexis-Calbiochemicals, 
Tokyo, Japan) and 5-HD (Sigma Chemicals, St. Louis, MO, USA) were dissolved in 
distilled water, and added to the KH perfusate to a final concentration of 10 µM and 200 
µM, respectively. We performed experiments in the following order: first a CTL, followed 
by ETOH, SEVO, ETOH+SEVO, CTL+CHE, and so forth until the first series of 
experiments were completed. This sequence was repeated a total of ten times.     
 
Determination of Myocardial Infarct Size 
At the end of experiments, the hearts were quickly frozen at –80 °C for 15 min, then 
sliced into 2 mm thick transverse sections from apex to base (6 slices/heart). After removing 
the right ventricle and defrosting, each slice was weighed and incubated at 37 °C with 1% 
triphenyltetrazolium chloride (Sigma Chemicals) in phosphate buffer (pH 7.4) for 10 min 
and then fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from 
pale unstained necrotic tissue.19 Each slice was photographed and the necrotic area was 
determined using Adobe Photoshop® CS (Adobe, CA, USA) and multiplied by the weight of 
the slice, then expressed as a fraction of left ventricle.   
 
Western Blot Analysis 
     Separate experiments were performed (n=4 in each group) to examine iNOS and eNOS 
expression. Myocardial tissue samples were collected before ischemia, and homogenized in 
ice-cold homogenizing buffer containing in mM: 250 sucrose, 20 HEPES (pH 7.5), 10 KCl, 2 
EGTA, 2 MgCl2, 25 NaF, 50 β-glycerophosphate, 1 Na3VO4, 1 PMSF, 1% Triton X and 
protease inhibitor leupeptin (10 µg/ml). The homogenate was centrifuged at 1000g and 4 °C 
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for 5 min. The supernatant was re-centrifuged at 10000g and 4 °C for 15 min. The protein 
concentration was estimated with a Bradford assay. Equivalent amounts (50 µg) of protein 
samples were loaded and separated on a 5-10% SDS-PAGE gradient gel, then electrically 
transferred overnight to a PVDF membrane (Millipore Co., Billerica, USA). After blocking 
with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), the 
membranes were incubated for 2 hr at 4 °C in TBS-T containing 5% milk and 1:200 dilution 
of rabbit primary antibody for iNOS and eNOS (H-174 and H-159, Santa Cruz Biotechnology, 
USA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase–labeled 
anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, UK). The same blot was stripped 
and re-blotted with antibodies to α-tubulin to confirm equal protein loading. Bound antibody 
signals were detected with enhanced chemiluminescence (Pierce Biotechnology, IL, USA) and 
visualized using VersaDoc 5000® Imaging System (Bio-Rad). Quantitative analysis of the 
band densities was performed by Quantity One® software (Bio-Rad).  
 
Statistical Analysis 
All data are expressed as mean±SD. Two-factor repeated-measures analysis of 
variance was used to evaluate differences over time between groups. If differences were 
observed, a Tukey post-hoc test was used to confirm the significance of differences between 
groups. The differences in expressions of iNOS and eNOS were determined by unpaired 
Student’s t test. Power analysis demonstrated a sample size of n=10 hearts per group was 
sufficient. A value of p<0.05 was considered statistically significant. 
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Results 
Of a total of 92, 10 hearts were not used secondary to intractable ventricular 
fibrillation after reperfusion (four in CTL, three in CTL+CHE, two in CTL+5HD and one 
EtOH+SEVO+CHE) and 2 hearts were not used due to aortic rupture. Additional hearts 
were studied until each group had n=10 successful experiments. There was no significant 
difference in body weight among groups. Serum ethanol levels at time of sacrifice was 
2.7±0.5 mmol/L. Ethanol was not detected in the effluent of the 10 EtOH hearts sampled 
after 50 min washout but before ischemia or sevoflurane exposure. There was no difference 
in liver enzymes levels between EtOH and CTL animals. The concentration of sevoflurane 
in the coronary perfusate after 10 min of exposure was 0.36±0.09 mM. Sevoflurane was not 
detected in the effluent during the baseline, ischemic, and reperfusion periods.  
 
Hemodynamics   
Baseline LVDP, +dP/dtmax, -dP/dtmin and CF were similar among the 8 groups. 
Administration of sevoflurane or treatment with CHE and 5-HD did not significantly affect 
LVDP or CF. Recovery of LVDP was greater in EtOH, SEVO, and EtOH+SEVO compared 
with CTL throughout the reperfusion period. Recovery of LVDP in EtOH+SEVO hearts was 
abolished by administration of CHE and 5-HD. Treatment with CHE and 5-HD alone did not 
affect the recovery of LVDP.  LVEDP increased to 600% of baseline in CTL after ischemia-
reperfusion. The increase in LVEDP was significantly less in EtOH, SEVO, and 
EtOH+SEVO compared with CTL hearts during reperfusion period. LVEDP in CHE and 5-
HD groups was similar to that of CTL hearts. Treatment with CHE and 5-HD alone did not 
affect the increased LVEDP.  
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All groups had reduced +dP/dtmax  after reperfusion compared with baseline. 
Recovery of +dP/dtmax was significantly greater in SEVO, EtOH and SEVO+EtOH 
compared with CTL hearts, but not in hearts pretreated with CHE and 5-HD. Changes of -
dP/dtmin during the reperfusion period were similar to those of +dP/dtmax. There was no 
significant difference in CF among all groups throughout the experiment. This suggests that 
changes in CF could not account for the improved contractile recovery of SEVO or ETOH 
hearts (Table 1). 
 
Myocardial Infarct Size 
Myocardial infarct size in EtOH and SEVO groups was significantly reduced by 
approximately 50% compared with control hearts (EtOH:27±6%, SEVO:23±7% vs. 
CTL:45±11%, p<0.001). The administration of sevoflurane in EtOH hearts decreased infarct 
size compared with EtOH alone (EtOH+SEVO:15±4%, vs. EtOH: 27±6%, p<0.001). 
Myocardial infarct size in EtOH and SEVO hearts pretreatment with CHE and 5-HD was not 
different compared with CTL hearts (EtOH+SEVO+CHE:44±12%, p=0.777, 
EtOH+SEVO+5-HD:45±9%, p=0.852 vs. CTL). Treatment with CHE and 5-HD alone did 
not affect the infarct size compared with the CTL group (p=0.884; 0.355, respectively, vs. 
CTL) (Figure 2).   
 
Western Blot analysis 
  The densities of iNOS and eNOS were normalized against that of CTL. Chronic 
EtOH consumption increased expression of eNOS whereas it reduced expression of iNOS 
compared with the CTL groups (Figure 3). Ethanol-treated and CTL hearts showed similar 
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iNOS and eNOS expression in the presence of CHE and 5-HD with and without sevoflurane 
exposure (data not shown). 
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Discussion 
We found that pretreatment with sevoflurane and regular ethanol consumption 
equally preconditioned hearts against ischemia-reperfusion injury. Furthermore, sevoflurane 
enhanced the cardioprotective effect of regular ethanol consumption resulting in smaller 
infarct size. This protection was abolished by inhibiting PKC or mitochondrial KATP 
channels, suggesting their role in mediating the observed cardiac preconditioning. Finally, 
we found that regular ethanol consumption increased eNOS expression and reduced iNOS 
expression. Our finding that hearts treated with sevoflurane or ethanol showed similar 
improved functional recovery, demonstrated by increased LVDP and lower LVEDP, as well 
as a nearly 50% decrease in infarct size, following ischemia-reperfusion is consistent with 
previous reports.12,20,21 We observed that despite a significant reduction of myocardial infarct 
size induced by the combination of ethanol and sevoflurane, compared with either 
preconditioning therapy alone, recovery of LVDP during reperfusion was comparable among 
SEVO, EtOH and SEVO+EtOH hearts. This disparity between the functional recovery and 
infarct size might be explained by myocardial stunning from global ischemia that affected a 
greater area of the LV than that susceptible to infarction.22,23   
A new finding of this study was that ethanol-induced preconditioning is enhanced by 
anesthetic-induced preconditioning. A possible mechanism for this effect may be that 
ethanol does not completely activate the signal transduction pathways eliciting 
cardioprotection. We previously demonstrated that exposure to 2.5 % ethanol for 6 weeks 
reduces ischemia-reperfusion injury to the same degree as 5%, 10%, and 20% ethanol for 6 
to 12 weeks.12 Thus, the ethanol dose used in the present study should induce the maximum 
ethanol-induced cardiac protection. Similarly, the sevoflurane dose (2%) used in the present 
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study has been previously shown to produce the maximum cardiac protection.24 The additive 
preconditioning effect by the combination of sevoflurane and ethanol suggests that there are 
some differences in either their mechanisms of action or degree of signaling activation. 
Opening of KATP channels is an important step in the signal transduction cascade of 
cardiac protection from both volatile anesthetics21 and chronic ethanol exposure.25 For 
example, Zaugg et al.26, demonstrated that sevoflurane increased mitochondrial flavoprotein 
oxidation, an index of mitochondrial KATP channel activity, and that this effect was 
completely abolished by chelerythrine (2 µM) in rat cardiomyocytes. Mitochondrial KATP 
channels are activated by NO27, a key mediator in late ischemic preconditioning.28 Others 
have shown that preconditioning with sevoflurane enhances the increased NO effluent 
induced by bradykinin and nitroprusside in isolated guinea pig hearts.17 Moreover, ethanol 
consumption increases serum NO production 30 min after drinking in humans.29 Our data 
and prior reports suggest that increased eNOS expression due to chronic ethanol 
consumption could result in increased NO production. This is consistent with a previous 
study demonstrating that ethanol increases NO production through modulation of eNOS 
expression.18 Recently, the importance of eNOS in myocardial ischemic protection was 
demonstrated in an eNOS knockout mice model.30 Thus, augmentation of mitochondrial 
KATP channel activity by increased NO with the combination of sevoflurane and chronic 
ethanol consumption might explain the additive cardioprotection in SEVO+EtOH hearts. 
Previous experiments suggest that inflammation plays a role ischemia-reperfusion 
injury.31 NO derived from iNOS mediates cardiac dysfunction by inducing production of 
pro-inflammatory cytokines.32 Cytokines such as interleukin-1β, interleukin-6, and tumor 
necrosis factor-alpha (TNF-α) are up-regulated rapidly in response to myocardial ischemia.33 
  
 
17 
Sevoflurane has been shown to reduce the production of TNF-α in patients undergoing 
coronary bypass surgery.34 Interestingly, a recent study found that the late phase of ethanol’s 
myocardial preconditioning correlated with reduced leukocyte-endothelial cell adhesive 
interactions, suggesting an anti-inflammatory effect.35 In the present study, with a 
crystalloid-perfused heart, leukocyte-endothelial cell adhesive interactions, though, is not a 
factor. Nevertheless, EtOH hearts demonstrated reduced iNOS expression before ischemia 
compared with CTL. Thus, regular ethanol consumption could attenuate the inflammatory 
response to myocardial ischemia resulting from increased NO production via iNOS. 
Although iNOS is thought to be absent in myocytes under physiologic conditions, there is 
evidence that iNOS is present in small vessel endothelium, vascular smooth muscle cells, 
and immune cells that infiltrate the heart.36  
Recent studies demonstrate that acute (as opposed to chronic) ethanol exposure fails 
to exert a cardioprotection when ethanol is present during ischemia-reperfusion.37 Although 
not withdrawn from the drinking water before sacrifice in this study, serum ethanol levels 
were low (2.7±0.5 mmol/L) at the time of sacrifice. Ethanol was washed out prior to 
ischemia using a crystalloid ethanol-free buffer. Ethanol was not detected after 50 min 
perfusion in the effluent. Ethanol freely diffuses in myocytes. Thus, tissue levels of ethanol 
were likely negligible at the time of study.  
  A limitation of the present study is that we did not directly measure PKC levels and 
mitochondrial KATP channel activity before and during ischemia-reperfusion. The doses of 
CHE and 5-HD used in the present study have been previously found to reduce PKC levels 
and inhibit mitochondrial KATP channel activity, respectively.
14,38
 Furthermore, we and other 
investigators have previously shown that the same concentrations of CHE and 5-HD inhibit 
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the preconditioning-like effects of ethanol or sevoflurane alone.14,25,38 Prolonged ingestion of 
ethanol may lead to changes in heart rate and blood pressure. Although we did not measure 
heart rate or blood pressure prior to sacrifice in this study, a previous study demonstrated 
that feeding 10 % ethanol (a much higher dose) for 40 weeks to guinea pigs did not alter 
hemodynamics compared with control39. Finally, animals were not randomized to each study 
group although the order of study was standardized. 
In conclusion, sevoflurane enhances cardiac preconditioning induced by regular 
ethanol consumption. Our findings suggest that PKC and mitochondrial KATP channels play 
a role in mediating this cardioprotection. NOS expression is altered by regular ethanol 
consumption.  
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Table Legend 
Table 1: Data are presented as mean ± SD. LVDP=left ventricular developed pressure; 
LVEDP=left ventricular end-diastolic pressure; CF=coronary flow; +dP/dt
max=
maximum 
rate of increase of LV pressure; -dP/dt
min= maximum rate of increase of LV pressure; 
CTL=control; EtOH=ethanol; SEVO=sevoflurane CHE=chelerythrine; 5-HD=5- 
hydroxydecanoate. *p<0.05 vs. CTL , n=10 for each group  
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                                                       Figure Legends 
 
Figure 1: Schematic illustration of the experimental protocol of this study.  All hearts were 
subjected to 30 min global ischemia followed by 120 min reperfusion. Anesthetic 
preconditioning (APC) was elicited by administration of sevoflurane (2% or 1 MAC) for 10 
min with a 10 min washout period. Ethanol-treated animals received 2.5% ethanol in their 
drinking water for 6 weeks. CTL=control; EtOH=ethanol; SEVO=sevoflurane; 
CHE=chelerythrine, PKC inhibitor; 5-HD=5-hydroxydecanoate, mitochondrial KATP channel 
inhibitor 
 
Figure 2: Infarct size as a percentage of LV in eight groups. Treatment with sevoflurane (1 
MAC) and 2.5 % ethanol for 6 weeks equally reduced infarct size compared with control. 
The combination of sevoflurane and 2.5 % ethanol conferred a further reduction of infarct 
size. This additional cardioprotective effect was abolished by CHE and 5-HD in 
SEVO+EtOH. 5-HD and CHE treatment alone did not affect infarct size. Data are presented 
as mean ± SD. *p<0.001 vs. CTL, #p<0.001 vs. EtOH and SEVO 
 
Figure 3: Western blot analysis of iNOS and eNOS from left ventricular samples before 
ischemia in control and ethanol-treated hearts (n=4 for each group). In ethanol-treated 
hearts, iNOS expression was significantly reduced and eNOS expression was significantly 
increased compared with control. *p<0.05 vs. CTL 
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(CHE or 5HD)
+SEVO/SEVO
-60 -40 -30 30 60 120
LVDP (mmHg)
CTL 113±17 39±7 33±8 26±8
EtOH 104±14 60±13* 56±13* 47±11*
SEVO 101±13 100±12 103±12 61±9* 58±8* 50±8*
EtOH+SEVO 110±16 106±20 110±17 66±8* 61±8* 50±9*
CTL+CHE 109±13 108±15   97±17 26±12 27±12 26±12
EtOH+SEVO+CHE 100±8   99±12   88±18 30±10 29±10 29±9
CTL+5-HD 107±16 108±16 102±17 41±11 39±10 36±10
EtOH+SEVO+5-HD 111±7 112±14 106±14 38±13 35±10 32±8
LVEDP (mmHg)
CTL 10±0 47±13 55±18 60±17
EtOH 10±0 24±21* 25±21* 27±20*
SEVO 10±0 10±3 10±2 24±7* 24±5* 26±7*
EtOH+SEVO 10±0   9±2 10±3 19±6* 20±6* 25±11*
CTL+CHE 10±0 10±3 13±7 52±20 49±23 48±24
EtOH+SEVO+CHE 10±0 10±2 15±13 46±17 50±19 49±20
CTL+5-HD 10±0   7±3   8±4 49±12 53±9 55±10
EtOH+SEVO+5-HD 10±0   8±4 10±4 56±18 58±17 57±19
CF (ml)
CTL 28±7 27±9 28±10 28±11
EtOH 27±4 26±10 26±10 25±11
SEVO 31±7 29±4 27±4 25±7 25±7 24±7
EtOH+SEVO 26±6 30±7 25±5 21±4 20±3 20±3
CTL+CHE 28±8 31±8 26±9 21±7 21±7 20±8
EtOH+SEVO+CHE 28±7 32±8 26±9 20±9 20±9 19±9
CTL+5-HD 29±5 26±6 26±5 28±7 28±7 27±8
EtOH+SEVO+5-HD 27±4 24±4 22±3 22±7 21±7 21±7
+dP/dtmax (mmHg-Es-1)
CTL 1735±310
 786±185   674±218 544±168
EtOH 1433±242 1114±197* 1085±212* 925±179*
SEVO 1479±251 1492±212 1529±224 1019±168* 1000±156* 910±124*
EtOH+SEVO 1588±257 1604±285 1623±232 1156±159* 1133±132* 953±162*
CTL+CHE 1566±232 1676±297 1443±349
  491±203   490±200 482±197
EtOH+SEVO+CHE 1442±145 1521±205 1368±268
  572±176   576±161 537±175
CTL+5-HD 1635±219 1683±203 1656±174
  730±212   700±200 660±225
EtOH+SEVO+5-HD 1653±137 1586±276 1485±259
  625±113   614±127 564±96
-dP/dtmin (mmHg-Es-1)
CTL -1470±252 -553±141 -483±124 -389±100
EtOH -1197±274 -913±203* -809±190* -709±182*
SEVO -1230±181 -1220±160 -1286±157 -815±120* -771±109* -694±106*
EtOH+SEVO -1318±192 -1261±271 -1344±175 -889±118* -853±114* -699±171*
CTL+CHE -1310±149 -1375±241 -1017±372 -355±144 -367±146 -375±153
EtOH+SEVO+CHE -1321±155 -1254±152 -1081±280 -408±142 -426±139 -413±132
CTL+5-HD -1473±149 -1546±209 -1510±228 -523±136 -486±113 -454±108
EtOH+SEVO+5-HD -1467±151 -1548±251 -1411±265 -524±146 -515±131 -378±356
         
Table 1. Hemodynamic Variables
reperfusion (min)baseline washout
